BR112017002003A2 - biomarcadores de doença renal policística e usos dos mesmos - Google Patents

biomarcadores de doença renal policística e usos dos mesmos

Info

Publication number
BR112017002003A2
BR112017002003A2 BR112017002003A BR112017002003A BR112017002003A2 BR 112017002003 A2 BR112017002003 A2 BR 112017002003A2 BR 112017002003 A BR112017002003 A BR 112017002003A BR 112017002003 A BR112017002003 A BR 112017002003A BR 112017002003 A2 BR112017002003 A2 BR 112017002003A2
Authority
BR
Brazil
Prior art keywords
protein
drp
patient
kinase
phosphorylated
Prior art date
Application number
BR112017002003A
Other languages
English (en)
Portuguese (pt)
Inventor
Bukanov Nikolai
Beskrovnaya Oxana
Moreno Sarah
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112017002003A2 publication Critical patent/BR112017002003A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
BR112017002003A 2014-08-04 2015-08-03 biomarcadores de doença renal policística e usos dos mesmos BR112017002003A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033031P 2014-08-04 2014-08-04
PCT/US2015/043497 WO2016022500A2 (en) 2014-08-04 2015-08-03 Biomarkers of polycystic kidney disease and uses thereof

Publications (1)

Publication Number Publication Date
BR112017002003A2 true BR112017002003A2 (pt) 2017-12-12

Family

ID=54035292

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002003A BR112017002003A2 (pt) 2014-08-04 2015-08-03 biomarcadores de doença renal policística e usos dos mesmos

Country Status (12)

Country Link
US (1) US10871495B2 (enExample)
EP (1) EP3177932B1 (enExample)
JP (2) JP6730252B2 (enExample)
KR (1) KR20170033436A (enExample)
CN (1) CN106716136B (enExample)
AU (1) AU2015301278A1 (enExample)
BR (1) BR112017002003A2 (enExample)
CO (1) CO2017001596A2 (enExample)
MX (1) MX2017001648A (enExample)
RU (1) RU2017106891A (enExample)
SG (1) SG11201700290SA (enExample)
WO (1) WO2016022500A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108700594B (zh) 2015-11-18 2021-06-29 建新公司 多囊性肾病的生物标志物及其用途
GB201719520D0 (en) * 2017-11-24 2018-01-10 Univ College Cardiff Consultants Ltd Neuroprotectvie peptide
KR102859441B1 (ko) * 2019-11-22 2025-09-12 서울대학교산학협력단 Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2374499A1 (en) 1999-05-24 2000-11-30 Avi Biopharma, Inc. Antisense to c-myc for treatment of polycystic kidney disease
US9006181B2 (en) 2004-07-21 2015-04-14 The Administrators Of The Tulane Educational Fund Treatment of renal dysfunction and multiple myeloma using PACAP compounds
EP1808694A1 (en) 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
WO2010141862A2 (en) 2009-06-05 2010-12-09 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
CN102018702B (zh) 2009-09-16 2012-07-18 北京大学 银杏内酯b的一种用途
US20140079769A1 (en) * 2010-10-01 2014-03-20 Fabiola Terzi Methods for predicting the progression and treating a chronic kidney disease in a patient
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
US10478446B2 (en) 2012-07-03 2019-11-19 Fondazione Centro San Raffaele Office Of Biotechnology Transfer Compounds for use in polycystic kidney disease
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide

Also Published As

Publication number Publication date
US10871495B2 (en) 2020-12-22
RU2017106891A (ru) 2018-09-06
RU2017106891A3 (enExample) 2019-03-14
JP2017525955A (ja) 2017-09-07
JP7005695B2 (ja) 2022-02-04
CN106716136A (zh) 2017-05-24
EP3177932B1 (en) 2021-07-14
KR20170033436A (ko) 2017-03-24
WO2016022500A3 (en) 2016-04-07
WO2016022500A2 (en) 2016-02-11
CN106716136B (zh) 2020-06-23
AU2015301278A1 (en) 2017-02-09
MX2017001648A (es) 2017-04-27
SG11201700290SA (en) 2017-02-27
EP3177932A2 (en) 2017-06-14
JP6730252B2 (ja) 2020-07-29
US20170227551A1 (en) 2017-08-10
JP2020170013A (ja) 2020-10-15
CO2017001596A2 (es) 2017-05-19

Similar Documents

Publication Publication Date Title
CO2019006485A2 (es) Anticuerpos y metodos de su utilizacion
BR112012009284A2 (pt) método e sistema para avaliar automaticamente a semelhança entre uma região geológica alvo de interesse e uma pluralidade de regiões geológicas conhecidas de interesse.
EP4614155A3 (en) Methods of assaying proteins
BR112016007348A2 (pt) membro de ligação específica que se liga ao receptor do fator de crescimento epidérmico humano 2 (her2) para uso em um método de tratamento do câncer em um paciente, método de tratamento de câncer em um paciente, método de identificação de um câncer em um paciente, método para prognosticar a resposta de um câncer
BR112015023262A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112014026990A2 (pt) anticorpo , ácido nucleico , vetores , célula hospedeira , composição farmacêutica , uso de um anticorpo e método para o tratamento de um paciente com necessidade de terapia.
BR112016016937A8 (pt) partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t
BR112014018970A8 (pt) Dispositivos de coleta de amostra com agentes de estabilização sanguínea
BR112016004324A2 (pt) anticorpos
BR112017023131A2 (pt) anticorpos anti- fcrn
WO2016015058A3 (en) Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
BR112018008799A2 (pt) método de prognóstico
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
BR112014018729A8 (pt) Método e aparelho para testar materiais de circulação perdidos para formações subterrâneas
MX2016011059A (es) Sistemas, dispositivos y metodos para verificacion de la integridad de muestras.
BR112015002634A2 (pt) matriz e sistema para preservar espécimes biológicos para análise qualitativa e quantitativa.
MX2024011859A (es) Biomarcadores de arn para angioedema hereditario
BR112016021679A2 (pt) proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
BR112019021352A8 (pt) Método para determinar e mitigar o risco de formação de cera de uma composição de hidrocarboneto, método para reduzir os riscos de formação de cera e sistema para uso de análise preditiva no gerenciamento de um processamento de hidrocarbonetos para determinar e mitigar a formação de cera
HK1244534A1 (zh) 重组疏螺旋体蛋白及其使用方法
BR112016024457A2 (pt) anticorpo isolado, imunoconjugado, uso do anticorpo, formulação farmacêutica, ácido nucleico isolado, célula hospedeira e método de produção de um anticorpo
CO2017001596A2 (es) Biomarcadores de enfermedad poliquística renal y usos de los mismos
BR112018009879A2 (pt) biomarcador da doença renal policística e seus usos
BR112016024742A2 (pt) método para a seleção de uma proteína, proteínas de ligação ao antígeno, anticorpos, imunoconjugado, formulação farmacêutica, uso do anticorpo, ácido nucleico e polipeptídeo

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]